Alnylam Pharmaceuticals Inc. has given an intellectual property license related to its InterfeRx program to Spanish RNAi-focused biotech Sylentis SA, a subsidiary of Grupo Zeltia.

With the non-exclusive licensing option, Sylentis plans to develop and commercialize a synthetic siRNA to treat glaucoma, Alnylam officials said in a news release. The Spanish company, which currently has a program in Phase 1/2 clinical trials, would owe Alnylam up front and milestone payments, in addition to royalties on products related to the InterfeRx license, once the licensing option is exercised.

No financial terms of the licensing agreement were disclosed.